Graham presented his findings in France Aug. 25, but already had encountered the resistance from supervisors.
 The controversy grew Friday when Grassley asked Merck, among other things, about an e-mail provided by Graham in which a Merck official complained that the FDA had not lived up to a prior agreement to alert the company before releasing any negative information about its products.
 Meanwhile, the European Medicines Agency in London announced it would review drugs similar to Vioxx.
 "We all take reasonable risks in our lives," the physician said.